These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31524211)

  • 41. Resveratrol reduces the hypoxia-induced resistance to doxorubicin in breast cancer cells.
    Mitani T; Ito Y; Harada N; Nakano Y; Inui H; Ashida H; Yamaji R
    J Nutr Sci Vitaminol (Tokyo); 2014; 60(2):122-8. PubMed ID: 24975222
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-angiogenic and anti-inflammatory effects of long-circulating liposomes co-encapsulating curcumin and doxorubicin on C26 murine colon cancer cells.
    Sesarman A; Tefas L; Sylvester B; Licarete E; Rauca V; Luput L; Patras L; Banciu M; Porfire A
    Pharmacol Rep; 2018 Apr; 70(2):331-339. PubMed ID: 29477042
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vascular targeting of doxorubicin using cationic liposomes.
    Wu J; Lee A; Lu Y; Lee RJ
    Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Redox-responsive mesoporous selenium delivery of doxorubicin targets MCF-7 cells and synergistically enhances its anti-tumor activity.
    Zhao S; Yu Q; Pan J; Zhou Y; Cao C; Ouyang JM; Liu J
    Acta Biomater; 2017 May; 54():294-306. PubMed ID: 28267598
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enhancing tumor chemotherapy and overcoming drug resistance through autophagy-mediated intracellular dissolution of zinc oxide nanoparticles.
    Hu Y; Zhang HR; Dong L; Xu MR; Zhang L; Ding WP; Zhang JQ; Lin J; Zhang YJ; Qiu BS; Wei PF; Wen LP
    Nanoscale; 2019 Jun; 11(24):11789-11807. PubMed ID: 31184642
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibiting Hypoxia and Chemotherapy-Induced Cancer Cell Metastasis under a Valid Therapeutic Effect by an Assistance of Biomimetic Oxygen Delivery.
    Jiang MS; Yin XY; Qin B; Xuan SY; Yuan XL; Yin H; Zhu C; Li X; Yang J; Du YZ; Luo LH; You J
    Mol Pharm; 2019 Nov; 16(11):4530-4541. PubMed ID: 31617723
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells.
    Pedrini I; Gazzano E; Chegaev K; Rolando B; Marengo A; Kopecka J; Fruttero R; Ghigo D; Arpicco S; Riganti C
    Mol Pharm; 2014 Sep; 11(9):3068-79. PubMed ID: 25057799
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers.
    Chen YL; Yang TY; Chen KC; Wu CL; Hsu SL; Hsueh CM
    Cell Oncol (Dordr); 2016 Oct; 39(5):411-433. PubMed ID: 27306525
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting tumor hypoxia with stimulus-responsive nanocarriers in overcoming drug resistance and monitoring anticancer efficacy.
    Xie Z; Guo W; Guo N; Huangfu M; Liu H; Lin M; Xu W; Chen J; Wang T; Wei Q; Han M; Gao J
    Acta Biomater; 2018 Apr; 71():351-362. PubMed ID: 29545193
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Normoxic Tumour Extracellular Vesicles Modulate the Response of Hypoxic Cancer and Stromal Cells to Doxorubicin In Vitro.
    Patras L; Fens MHAM; Vader P; Barendrecht A; Sesarman A; Banciu M; Schiffelers R
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32824972
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.
    Rohwer N; Cramer T
    Drug Resist Updat; 2011 Jun; 14(3):191-201. PubMed ID: 21466972
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth.
    Liu XQ; Xiong MH; Shu XT; Tang RZ; Wang J
    Mol Pharm; 2012 Oct; 9(10):2863-74. PubMed ID: 22924580
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Salidroside Promotes Sensitization to Doxorubicin in Human Cancer Cells by Affecting the PI3K/Akt/HIF Signal Pathway and Inhibiting the Expression of Tumor-Resistance-Related Proteins.
    Zeng Q; Nie X; Li L; Liu HF; Peng YY; Zhou WT; Hu XJ; Xu XY; Chen XL
    J Nat Prod; 2022 Jan; 85(1):196-204. PubMed ID: 34978808
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oxidative Stress Promotes Doxorubicin-Induced Pgp and BCRP Expression in Colon Cancer Cells Under Hypoxic Conditions.
    Pinzón-Daza ML; Cuellar-Saenz Y; Nualart F; Ondo-Mendez A; Del Riesgo L; Castillo-Rivera F; Garzón R
    J Cell Biochem; 2017 Jul; 118(7):1868-1878. PubMed ID: 28106284
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Extremely Effective Chemoradiotherapy by Inducing Immunogenic Cell Death and Radio-Triggered Drug Release under Hypoxia Alleviation.
    Zhu C; Guo X; Luo L; Wu Z; Luo Z; Jiang M; Zhang J; Qin B; Shi Y; Lou Y; Qiu Y; You J
    ACS Appl Mater Interfaces; 2019 Dec; 11(50):46536-46547. PubMed ID: 31751119
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin.
    Qiu L; Qiao M; Chen Q; Tian C; Long M; Wang M; Li Z; Hu W; Li G; Cheng L; Cheng L; Hu H; Zhao X; Chen D
    Biomaterials; 2014 Dec; 35(37):9877-9887. PubMed ID: 25201738
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Micelles of d-α-Tocopheryl Polyethylene Glycol 2000 Succinate (TPGS 2K) for Doxorubicin Delivery with Reversal of Multidrug Resistance.
    Hao T; Chen D; Liu K; Qi Y; Tian Y; Sun P; Liu Y; Li Z
    ACS Appl Mater Interfaces; 2015 Aug; 7(32):18064-75. PubMed ID: 26214761
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Star-shaped polymer of β‑cyclodextrin-g-vitamin E TPGS for doxorubicin delivery and multidrug resistance inhibition.
    Yang C; Qin Y; Tu K; Xu C; Li Z; Zhang Z
    Colloids Surf B Biointerfaces; 2018 Sep; 169():10-19. PubMed ID: 29747026
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
    Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
    Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
    Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
    Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.